Aldeyra Therapeutics (ALDX) Discloses Promising Outcome from Clinical Trials of Topical Dermatologic NS2
On Tuesday, August 9, 2016, Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a biotechnology company involved in the commercialization of products that treat diseases thought to be related to endogenous aldehydes, made public the results of a randomized, parallel-group, double-blind, vehicle-controlled, multi-center clinical trial of topical dermatologic NS2 for the treatment of the dermal manifestations of Sjögren-Larsson Syndrome (SLS). The company, which is based in Lexington, Massachusetts, first became aware of SLS in 2012 and made the decision to employ its knowledge of aldehyde traps to combat the disease. The encouraging conclusion of these clinical trials marks, therefore, a major milestone for Aldeyra…







